Lockheed Martin Corporation vs GeneDx Holdings Corp — how do they compare? Lockheed Martin Corporation trades at $607 (market cap $137.96B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Lockheed Martin Corporation is far larger — about 56.5× GeneDx Holdings Corp's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| LMT | WGS | |
|---|---|---|
Market Cap | $137.96B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $676.70 | $167.51 |
52-Week Low | $431.56 | $34.51 |
Enterprise Value | $154.71B | $2.48B |
Dividend Yield | 2.31% | — |
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $606.71, up 0.59% on the day, near its consensus price target of $608. The stock shows bullish technical momentum with strong moving average signals and is supported by a record $230.4 billion backlog as of Q2 2026 (Seeking Alpha, August 4, 2026). Recent earnings beat expectations in Q2 2026 with EPS of $7.94 versus $7.22 estimated, though Q4 2025 and Q1 2026 results missed. The company maintains robust cash flow, with 2025 operating cash flow at $8.56 billion, and benefits from major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, August 11, 2026).
Outlook is positive due to strong defense spending trends and execution, but risks include earnings volatility and debt levels. The stock offers steady dividends and growth potential, with analyst consensus leaning bullish. Key risks involve reliance on government contracts and macroeconomic pressures on defense budgets.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Trailing returns across standard periods
Latest headlines on both assets
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →